Precision Medicine Approaches When Prostate Cancer Akts Up.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30206162.
- Also identified by DOI 10.1158/1078-0432.CCR-18-2491.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ipatasertib combined with abiraterone in PTEN-null prostate cancer improved progression-free survival in a randomized phase II study of patients with metastatic castration-resistant prostate cancer (mCRPC), providing clinical evidence of reciprocal activation between the Akt and androgen receptor (AR) pathways. These data revive the rationale for targeting PTEN loss in prostate cancer.<i>See related article by de Bono et al., p. 928</i>.
Medical subject headings
- Prostatic Neoplasms, Castration-Resistant